http://apps.asco.org/ePlanner/AM2011.aspx
Fri, Jun 3
2:00 PM - 6:00 PM
E450b (Location)
Abstract #6521
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
Olatoyosi Odenike, MD
Poster Board: #13
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
Olatoyosi Odenike
Honoraria - Celgene
Research Funding – TopoTarget
--------------------------------------------------
Fri, Jun 3
5:00 PM - 6:00 PM
Arie Crown Theater (Location)
Discussion
Olatoyosi Odenike
Consultant or Advisory Role - Amgen; Cephalon; Genzyme (U); Incyte; MGI Pharma
Honoraria - Celgene; Genzyme
Research Funding - MGI Pharma; TopoTarget
Other Remuneration - Gloucester Pharmaceuticals
Sendt fra ProInvestor gruppen
Fri, Jun 3
2:00 PM - 6:00 PM
E450b (Location)
Abstract #6521
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
Olatoyosi Odenike, MD
Poster Board: #13
A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies.
Olatoyosi Odenike
Honoraria - Celgene
Research Funding – TopoTarget
--------------------------------------------------
Fri, Jun 3
5:00 PM - 6:00 PM
Arie Crown Theater (Location)
Discussion
Olatoyosi Odenike
Consultant or Advisory Role - Amgen; Cephalon; Genzyme (U); Incyte; MGI Pharma
Honoraria - Celgene; Genzyme
Research Funding - MGI Pharma; TopoTarget
Other Remuneration - Gloucester Pharmaceuticals
Sendt fra ProInvestor gruppen
